Myriad Genetics, Inc. (MYGN) key performance indicators and operating metrics (37 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Total test results delivered | 379K | FY2026-Q2 |
| Adjusted earnings per share | -0.09 USD_per_share | FY2026-Q1 |
| GeneSight test revenue | 36.8M | FY2026-Q2 |
| Women's Health revenue | 88.5M | FY2025-Q4 |
| Oncology revenue | 84.7M | FY2025-Q4 |
| Adjusted earnings before interest, taxes, depreciation, and amortization | 14.3M | FY2025-Q4 |
| Cancer Care Continuum product volumes | 95K | FY2026-Q2 |
| Mental Health product volumes | 140K | FY2026-Q2 |
| Prenatal Health product volumes | 144K | FY2026-Q2 |
| Non Us revenue | 13.2M | FY2026-Q2 |
| US revenue | 177.5M | FY2026-Q2 |
| Adjusted operating expenses | 150.5M | FY2026-Q2 |
| Adjusted operating cash flow | -7.7M | FY2026-Q2 |
| Cancer Care Continuum revenue | 114.1M | FY2026-Q2 |
Back to MYGN overview · MYGN earnings · MYGN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.